This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
6-phosphogluconate dehydrogenase
From Proteopedia
(Undo revision 2496628 by Alexander Berchansky (Talk)) |
|||
| Line 13: | Line 13: | ||
6PGD deficiency is an autosomal hereditary disease which manifests itself by abnormal breakdown of red blood cells. Treatment involves avoidance of drugs or foods which can cause hemolysis. | 6PGD deficiency is an autosomal hereditary disease which manifests itself by abnormal breakdown of red blood cells. Treatment involves avoidance of drugs or foods which can cause hemolysis. | ||
| - | |||
| - | == Relevance == | ||
| - | |||
| - | == Structural highlights == | ||
==3D structures of 6-phosphogluconate dehydrogenase== | ==3D structures of 6-phosphogluconate dehydrogenase== | ||
Revision as of 07:45, 25 October 2015
Function
6-phosphogluconate dehydrogenase (6PGD) catalyzes the decarboxylation reduction of 6-phosphogluconate (6PG) to ribulose 5-phosphate and CO2. This reaction is part of the pentose phosphate pathway. NADP is a cofactor in this reaction and is converted to NADPH.
Disease
6PGD deficiency is an autosomal hereditary disease which manifests itself by abnormal breakdown of red blood cells. Treatment involves avoidance of drugs or foods which can cause hemolysis.
3D structures of 6-phosphogluconate dehydrogenase
Updated on 25-October-2015
